E.C.M. RES.
PRESCRITTIVE ADDRESS
Hypoglycemics, hypopolypemizers, antibiotics and PPIs
between guidelines and AIFA Notes

13 February 2027
ICS Maugeri Congress Centre - PAVIA

TYPOLOGY

RES

FREE

DATE

13/02/2027

END DATE

13/02/2027
Sign in to join the course

Scientific rationale

Theprescribed appropriateness has become one of the central themes of contemporary medicine, at the intersection of quality of care, patient safety and system sustainability. In a population that ages and accumulates chronic pathologies, the risk is not only to prescribe too little, but also to prescribe too much, too long or the wrong patient. Alongside the decision to start a drug acquires equal dignity that, often neglected, to deprescribe: reduce, suspend or reevaluate therapies that have exhausted their indication. In Italy, moreover, appropriateness is not only a clinical principle but a regulatory instrument: the Notes AIFA bind the reimbursement of entire classes of drugs to explicit criteria, and should be known in the current version — some have been reworked or unified recently. This morning he addresses four classes among the most prescribed, each with his own message of appropriateness and, where he exists, with its AIFA Note: He's the one hypoglycemic (customizedtarget, cardiorenal protection, Therapeutic Plans); He's the one ipolymerizing (global cardiovascular risk and Note 13); antibiotics (stewardship and PNCAR); and Protonic pump inhibitors (deprescription and the new Note that unifies the previous ones). For each class, two essential relationships: the clinical message and the regulatory or territorial bond. Meeting the doctor of general medicine with the diabetologist, cardiologist, infectious, internist and pharmacist — key figure of appropriateness at the time of dispensation, adherence and therapeutic reconciliation — the day builds a shared language on the rational use of the drug along the path of the patient. The contents are anchored to the international guidelines and primary sources verified, in full independence from commercial interests: therapies are treated by pharmacological class, never by commercial name, as required by ECM training.

WITH THE PATROCINIUS OF

START
13 February 2027
END OF COURSE
13 February 2027
TYPOLOGY
RES
LOCATION
ICS Maugeri Congress Centre - PAVIA
PARTICIPANTS
100
TARGETS
SURGERY MEDICINAL PRODUCTS - PHARMACEUTICALS

REFERENCE SPIPLINES:
PRIMARY ASSISTANCE MEDICINE (MAP) - INTERNAL MEDICINE - METABOLITICAL AND DIABETOLOGY MALACTS - INFECTS - GASTROENTEROLOGY - FARMACIA OSPEDALIERA - FARMACIA TERRITORIAL
ECM ID
752 - 502341
N. CREDITS RES
5,2
REGISTERING QUOTA
Free
E-MAIL
info@studio-congressi.com
Studio Congressi s.r.l.
VAT: 01975530187
Reg. Companies of Pv: 01975530187
R.E.A.: 235792
Social Capital: € 260.000,00

Studio Congressi s.r.l. and Med Tech Science s.r.l.
Avenue of Liberty, 17 | 27100 Pavia (PV)
📞 +39.0382.21424 | +39.351.8055151
info@studio-congressi.com
medtechscience2@gmail.com
Code Recipient SDI BA6ET11

Med Tech Science Ltd.
VAT No: 02080160183
Reg. Pv: 02080160183
R.E.A.: 244029
Social Capital: € 100,000,00

Studio Congressi s.r.l. and Med Tech Science s.r.l.
Avenue of Liberty, 17 | 27100 Pavia (PV)
📞 +39.0382.21424 | +39.351.8055151
info@studio-congressi.com
medtechscience2@gmail.com
Code Recipient SDI BA6ET11

Studio Congressi s.r.l.
VAT: 01975530187
Reg. Companies of Pv: 01975530187
R.E.A.: 235792
Social Capital: € 260.000,00

Med Tech Science Ltd.
VAT No: 02080160183
Reg. Pv: 02080160183
R.E.A.: 244029
Social Capital: € 100,000,00